Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | PRKCI | P41743 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 10/20 | 0.41 |
| ▸ | JAK1 | P23458 | 10/20 | 0.41 |
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | TYK2 | P29597 | 5/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588316 | 1.00 | AXL (0.56) | AXLPRKCIMGLLJAK2JAK1 | |
| SCHEMBL28735132 | 0.87 | AXL (0.56) | AXLPRKCIMGLLJAK2JAK1 | |
| SCHEMBL29588238 | 0.87 | AXL (0.56) | AXLPRKCIMGLLJAK2JAK1 | |
| SCHEMBL29713778 | 0.85 | AXL (0.54) | AXLPRKCIJAK2JAK1JAK3 | |
| SCHEMBL1154763 | 0.85 | AXL (0.54) | AXLPRKCIJAK2JAK1JAK3 | |
| SCHEMBL12876007 | 0.83 | AXL (0.53) | AXLPRKCIMGLLJAK2JAK1 | |
| SCHEMBL2115690 | 0.83 | AXL (0.55) | AXLPRKCIMGLLJAK1JAK3 | |
| SCHEMBL12876546 | 0.83 | AXL (0.55) | AXLPRKCIJAK2JAK1JAK3 | |
| SCHEMBL30985188 | 0.83 | AXL (0.55) | AXLPRKCIMGLLJAK1JAK3 | |
| SCHEMBL29378769 | 0.83 | AXL (0.55) | AXLPRKCIJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12590088-B2 | Jak inhibitor compound and pharmaceutical composition including the same | KOREA PHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12479841-B2 | Anthelmintic compounds comprising azaindoles structure | INTERVET, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20240116920-A1 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | KOREA PHARMA CO., LTD. (KR) | 2024-04-11 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7879844-B2 | useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| CN-101578285-A | Fused pyridine compound | ASTELLAS PHARMA INC (JP) | 2009-11-11 | — | — | CN | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-101351466-A | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2009-01-21 | — | — | CN | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
| EP-1910358-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007919-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | AXL 1363/4885PRKCI 197/4885MGLL 4631/4885 |
| US-12479841-B2 | Anthelmintic compounds comprising azaindoles structure | AADAC, HNMT, NISCH | AXL 4153/4885PRKCI 3638/4885MGLL 1995/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | AXL 4879/4885PRKCI 2758/4885MGLL 490/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | AXL 1887/4885PRKCI 293/4885MGLL 4859/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | AXL 1363/4885PRKCI 197/4885MGLL 4631/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | AXL 313/4885PRKCI 179/4885MGLL 4547/4885 |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, JAK2 | AXL 973/4885PRKCI 340/4885MGLL 4570/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | AXL 4168/4885PRKCI 1830/4885MGLL 1/4885 |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, IRAK3 | AXL 760/4885PRKCI 416/4885MGLL 4211/4885 |
| US-20240116920-A1 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | JAK1, JAK2, JAK3 | AXL 1817/4885PRKCI 285/4885MGLL 3596/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | AXL 4168/4885PRKCI 1830/4885MGLL 1/4885 |
| US-12590088-B2 | Jak inhibitor compound and pharmaceutical composition including the same | JAK1, JAK2, JAK3 | AXL 611/4885PRKCI 55/4885MGLL 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.